BOULDER, Colo.–(BUSINESS WIRE)–miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today it had received the Colorado BioScience Association’s 2009 Rising Star of the Year Award. The award, which recognizes a Colorado life sciences company that has demonstrated it is “one to watch,” was presented at the Association’s Annual Awards Dinner on November 10 in Denver.
“We are honored to have been recognized by the Colorado BioScience Association with this award,” said William S. Marshall, Ph.D., President and CEO of miRagen Therapeutics, Inc. “It’s particularly gratifying to have a group of industry peers acknowledge our company’s diligent efforts to produce life changing medicines.”
MicroRNAs have emerged as an important class of small RNAs encoded in the genome. They act to control the expression of sets of genes and entire pathways and are thus thought of as master regulators of gene expression. Recent studies have demonstrated that microRNAs are responsible for many diseases. Because they are single molecular entities that dictate the expression of fundamental regulatory pathways, microRNAs represent potential drug targets of unprecedented power.
About miRagen Therapeutics, Inc.
Cardiovascular disease is the leading cause of death globally. Astonishingly, in the United States, every 37 seconds a person dies from cardiovascular disease. For survivors, life changes dramatically after an adverse heart event. Because of the significant toll that cardiovascular and muscle disease takes on patients, miRagen Therapeutics, Inc. was founded in 2007 to develop innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease. Only recently discovered, miRNAs are short, single-stranded RNA molecules encoded in the genome that regulate gene expression and play a vital role in influencing the pathways responsible for cardiovascular and muscle disease. Principally funded through venture capital investments, miRagen combines world recognized leadership in cardiovascular medicine with unprecedented in-house expertise in miRNA biology and chemistry. For more information, please visit: www.miRagenTherapeutics.com.